⌘K
t
OptiBiotix Health plc confirmed its issued share capital and total voting rights as 97,943,161 shares on 24 October 2024. The Company also reported an invalid allotment of 3,125,000 shares, entered onto its register in August 2024 due to an administrative error, which it is in the process of correcting. These Invalid Allotment Shares have not been notified to the market nor admitted to trading on AIM.
| Date | 24 Oct 2024 |
| Time | 07:00:06 |
| Category | Capital structure |
| ID | 3839J |
OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")
Total Voting Rights
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.
This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.
|
For further information, please contact: OptiBiotix Health plc |
||
|
Neil Davidson, Chairman |
Contact via Walbrook below |
|
|
Stephen O'Hara, Chief Executive |
|
|
|
|
|
|
|
Cairn Financial Advisers LLP (NOMAD) |
Tel: 020 7213 0880 |
|
|
Liam Murray / Jo Turner / Ludovico Lazzaretti |
|
|
|
|
|
|
|
Peterhouse Capital Limited (Broker) |
Tel: 020 7220 9797 |
|
|
Duncan Vasey / Lucy Williams |
|
|
|
|
|
|
|
Walbrook PR Ltd |
Mob: 07876 741 001 |
|
|
Anna Dunphy |
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.